Business Wire

Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date

Share

The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/

Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation).

The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company.

“The Citation CJ3 Gen2 delivers an unmatched experience from day one—thanks to its exceptional range, payload and efficiency, combined with new productivity and comfort features,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Customers like Shannon and Dave will undoubtedly appreciate this aircraft, our most comprehensive Gen2 investment to date.”

Certified by the Federal Aviation Administration in October 2025, the aircraft was designed based on customer feedback via a Customer Advisory Board made up of owners, pilots and mechanics helping to create the ultimate aircraft experience. This feedback was key in every detailed enhancement in the aircraft, from cockpit to cabin.

“After extensive consideration of the competition, there was no equal for handling, service and support, training and reliability in the entry level jet category than the CJ3 Gen2,” said Shannon Day. “When we decided to upgrade our mission capabilities, staying in the Citation family was an easy decision. The CJ3 Gen2 is a great next step in my aviation journey and I’m looking forward to the advances in this aircraft like autothrottles, an externally serviceable lavatory and more legroom for a 6’3” pilot.”

The cockpit in the CJ3 Gen2 provides an extra 4.5 inches (11.4 cm) of legroom for the pilot, improving entry and egress from the pilot’s seat before and after flight. It offers a proven and trusted avionics system with the latest Garmin G3000 software and hardware, including:

  • Garmin Autothrottles to reduce pilot workload and provide flight-envelope protection
  • Intuitive touchscreen interface via Garmin Touchscreen Controllers
  • GDL60 for aircraft connectivity, including remote transmission of flight plans, automatic database updates as well as wireless transmission of aircraft diagnostic data

The fully customizable luxury interior allows customers to create the ideal environment for their specific mission with seating for up to 10 occupants. For added convenience, the Citation CJ3 Gen2 includes an externally serviceable lavatory.

“As a Cessna Citation owner since 2007, the brand has consistently earned my trust with a proven heritage, superior reliability and one of the strongest service and support networks in the industry,” Mecartney added. “The aftermarket support has always been responsive, efficient and predictable—which is invaluable as an owner-pilot. Choosing the CJ3 Gen2 felt like a natural continuation of a relationship and an aircraft lineage that I’ve relied on for nearly two decades.”

Textron Aviation delivers unmatched Aftermarket support through a global network designed to keep customers flying. With 20 company-owned service centers worldwide, 21 Authorized Service Facilities (ASFs) for Citation jets and more than 80 Mobile Service Units (MSUs), expert help is always within reach. The company’s expanded parts distribution network—with seven distribution centers and 17 stockrooms globally—offers same-day shipping and online ordering for over 150,000 unique part numbers. Textron Aviation Parts Distribution is backed by a team of more than 600 dedicated professionals and an expanded global customer support team, providing customers with the assistance they need wherever they are. The Aftermarket team offers 24/7 AOG support, delivering fast, reliable solutions that minimize downtime and maximize aircraft availability.

With a maximum range of 2,040 nautical miles (3,778 kilometers) and a maximum payload of 2,135 lbs. (968.4 kg), the Citation CJ3 Gen2 offers excellent range, payload and field performance to enable pilots to achieve a variety of missions in extensive conditions.

Learn more about the iconic Citation CJ3 family at cessna.txtav.com.

About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight. For more information, visit www.txtav.com.

About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems. For more information, visit: www.textron.com.

Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260108455097/en/

Contacts

Media Contact
Kate Flavin
+1.316.252.7780
kflavin@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftxtav.com%2F&e
sheet=54392438&newsitemid=20260108455097&lan=en-US&anchor=txtav.com&index=7&md5=
4882e31d291070744a83ed90568d947a

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press Release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press Release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press Release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press Release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press Release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye